Hey @Joey D I'm certain it's been said before (possibly even by me) but I just want to say that your efforts to keep people here informed, particularly given your proximity to the healthcare industry, are very much appreciated.
Thank you! Weirdly enough, I've found keeping up with the COVID information to be a good way to deal with the whole pandemic since it makes me feel like I know what's going on. Sure, there's a bunch of stuff I don't know, but knowing what to expect, how to prepare for it, and most importantly how to stay safe has certainly helped my mental state these past two years. Plus, we're told in the COVID meetings that I'm in that we can and should be a defense against misinformation.
===
With some more good news, the FDA has just granted EUA to AstraZeneca’s long-acting monoclonal antibodies called Evusheld (that can't be a word) to be used as a prophylaxis for certain individuals. Essentially this gives people 12 and up who legitimately cannot be vaccinated a way to get protection from COVID. It's not as effective as the vaccines we have, but it's better than nothing, especially for an immunocompromised individual.
The FDA authorized new long-acting monoclonal antibodies for the pre-exposure prevention of COVID-19 in certain adults and pediatric individuals.
www.fda.gov
Also, I'm not sure if this got posted or not, but last week the FDA also updated the EUA for bamlanivimab and etesevimab (a monoclonal antibody treatment) to allow newborns and up to be able to receive it. This is huge since there really hasn't been an effective treatment for young kids who are really sick.
FDA revised the EUA of bamlanivimab and etesevimab, administered together, to treat mild to moderate COVID-19 in all younger pediatric patients, including newbo
www.fda.gov
===
This is also an interesting read about where COVID could go after Omicron.
The rapid spread of new variants offers clues to how SARS-CoV-2 is adapting and how the pandemic will play out over the next several months.
www.nature.com
The gist of it is that there are a few ways SARS-CoV-2 could evolve.
The first is that it seems like it could become endemic and shares similar patterns to human coronavirus 229E, which most of us have probably gotten more than once in our lives since it manifests itself as the common cold. However, one of the bad things about SARS-CoV-2 sharing similarities to 229E is that 229E constantly evolves to evade the body's immune response.
There is also some thought that SARS-CoV-2 could become like respiratory syncytial virus (RSV) which is a disease that typically affects kids. It's not a good disease for kids at all and is the leading cause of hospitalization in infants. My son got it when he was six months old and spent a week in the hospital and was on high flow oxygen for most of it. The bad thing about this would be it would be another thing parents of newborns need to worry about, but since we already have a vaccine, it's likely we could offer decent protection for kids. Adults would probably need to get it too much like we do with the pertussis vaccine.
Finally, SARS-CoV-2 could become like either Influenza A or Influenza B depending on how quickly it evolves. If it's like A, that means it'd evolve fairly rapidly and vaccines would become less and less effective against it and need to be constantly updated. If it's like B, it wouldn't evolve as quickly and the vaccines would be more effective.
Ideally, I think SARS-CoV-2 ending up like the common cold would be the best outcome. It could even lead to a seasonal vaccine that protects you from getting the common cold and I would pay good money to not have to suffer a cold, or suffer it for a day or two instead of weeks on end.